2015
DOI: 10.3109/10428194.2015.1050666
|View full text |Cite
|
Sign up to set email alerts
|

Bortezomib plus CHOP for the treatment of HIV-associated plasmablastic lymphoma: clinical experience in three patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
13
0

Year Published

2016
2016
2024
2024

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 28 publications
(14 citation statements)
references
References 13 publications
0
13
0
Order By: Relevance
“…Reanalysis of our gene expression data (3 EBV + PT-PBL vs 20 EBV + PT-DLBCL, fold change 2, FDR < 0.05[ 95 ]) confirmed enhanced MYC signaling and demonstrated unfolded protein response endoplasmic reticulum stress signaling in PBL (unreported data). These findings provide an explanation for the success of bortezomib treatment in PBL case reports[ 96 , 97 ] and suggest that BET bromodomain inhibitors may represent a potential new therapeutic strategy, as has been successfully demonstrated in experimental models of multiple myeloma[ 98 ].…”
Section: Discussionmentioning
confidence: 94%
“…Reanalysis of our gene expression data (3 EBV + PT-PBL vs 20 EBV + PT-DLBCL, fold change 2, FDR < 0.05[ 95 ]) confirmed enhanced MYC signaling and demonstrated unfolded protein response endoplasmic reticulum stress signaling in PBL (unreported data). These findings provide an explanation for the success of bortezomib treatment in PBL case reports[ 96 , 97 ] and suggest that BET bromodomain inhibitors may represent a potential new therapeutic strategy, as has been successfully demonstrated in experimental models of multiple myeloma[ 98 ].…”
Section: Discussionmentioning
confidence: 94%
“…The use of antimyeloma agents has been based on the fact of the plasmacytic differentiation of PBL cells and on the detection of common genetic abnormalities between ΜΜ undergoing blastic transformation and PBL [ 19 ] although the experience is limited to case reports. The proteasome inhibitor bortezomib constitutes the cornerstone of frontline treatment in MM achieving rapid responses, protecting kidney function, and overcoming the adverse prognosis of poor cytogenetics.…”
Section: Discussionmentioning
confidence: 99%
“…The proteasome inhibitor bortezomib constitutes the cornerstone of frontline treatment in MM achieving rapid responses, protecting kidney function, and overcoming the adverse prognosis of poor cytogenetics. In addition, bortezomib has been shown to be effective in patients with post-germinal center (GC) diffuse large B-cell lymphoma (DLBCL), inducing higher response and survival rates when used in combination with anthracycline-containing regimens [ 19 ] and has been shown promising in PBL patients in combination with CHOP or CHOP-like regimens both in HIV-positive [ 9 ] and in HIV-negative patients [ 20 ]. As a result, the combination of CHOP plus bortezomib appeared a suitable choice for our patient.…”
Section: Discussionmentioning
confidence: 99%
“…In a short series, out of six patients treated with bortezomib alone, five achieved a PR – two as frontline therapy and three as a salvage treatment 45. Bortezomib has been used in combination with CHOP as frontline therapy in three HIV-associated PbL patients, all of them achieved a CR, and two of them were alive 14 and 22 months after V-CHOP 46. However, the most frequently used chemotherapy regimen in combination with bortezomib has been infusional EPOCH.…”
Section: Treatmentmentioning
confidence: 99%